Skip to main content
SpringerLink
Log in

Zwei neue Hoffnungen auf Progressionshemmung

Idiopathische Lungenfibrose

  • journal club
  • Published:
Pneumo News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Raghu G et al. Am J Respir Crit Care Med 2011;183:788–824.

    Article  PubMed  Google Scholar 

  2. Martinez FJ et al. Ann Intern Med 2005;142:963–7

    Article  PubMed  Google Scholar 

  3. Noble PW, Albera C, Bradford WZ, et al. Lancet 2011;377: 1760–9.

    Article  PubMed  CAS  Google Scholar 

  4. King TE Jr et al. N Engl J Med. 2014;370(22):2083–92.

    Article  PubMed  CAS  Google Scholar 

  5. Richeldi L, du Bois RM, Raghu G et al. N Engl J Med. 2014;370(22):2071–82.

    Article  PubMed  CAS  Google Scholar 

  6. Bonella F et al. Dtsch Med Wochenschr 2013;138(11):518–23.

    Article  PubMed  CAS  Google Scholar 

  7. Hunninghake GM. N Engl J Med. 2014;370(22):2142–3.

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Richeldi L, du Bois RM, Raghu G et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071–82.

    Article  PubMed  CAS  Google Scholar 

  • King TE Jr, Bradford WZ, Castro-Bernardini S et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik V, Pneumologie Herz-Thorax-Zentrum Fulda, Klinikum Fulda gAG, Pacelliallee 4, 36043, Fulda, Deutschland

    Philipp Markart (Direktor, Stellvertretender Leiter Schwerpunkt)

  2. „Fibrosierende Lungenerkrankungen“, Universitätsklinikum Giessen Marburg GmbH, Klinikstrasse 36, 35392, Giessen, Deutschland

    Philipp Markart (Direktor, Stellvertretender Leiter Schwerpunkt) &  Andreas Günther (Chefarzt, Leiter Schwerpunkt)

  3. AGAPLESION Pneumologische Klinik Waldhof-Elgershausen, 35753, Greifenstein, Deutschland

    Andreas Günther (Chefarzt, Leiter Schwerpunkt)

Authors
  1. Philipp Markart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philipp Markart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markart, P., Günther, A. Zwei neue Hoffnungen auf Progressionshemmung. Pneumo News 6, 32–33 (2014). https://doi.org/10.1007/s15033-014-0025-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-014-0025-3

Search

Navigation